Feasibility of such an approach was recently shown using another γ‐secretase substrate, BCMA, for treatment of multiple myeloma with chimeric antigen receptor (CAR) T cells in a mouse model and is currently tested in a clinical trial for multiple myeloma, again using CAR T‐cell therapy (Pont et al, 2019). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.